CN106572976A - 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途 - Google Patents

包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途 Download PDF

Info

Publication number
CN106572976A
CN106572976A CN201580017915.6A CN201580017915A CN106572976A CN 106572976 A CN106572976 A CN 106572976A CN 201580017915 A CN201580017915 A CN 201580017915A CN 106572976 A CN106572976 A CN 106572976A
Authority
CN
China
Prior art keywords
pharmaceutical composition
compound
composition according
amino
phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580017915.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·塑伊雷尔
F·特格特迈尔
R·申策尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verinos Operations GmbH
Original Assignee
Vasopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasopharm GmbH filed Critical Vasopharm GmbH
Priority to CN202110640860.1A priority Critical patent/CN113521017A/zh
Publication of CN106572976A publication Critical patent/CN106572976A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201580017915.6A 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途 Pending CN106572976A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110640860.1A CN113521017A (zh) 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162727.3 2014-03-31
EP14162727.3A EP2926805B1 (en) 2014-03-31 2014-03-31 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PCT/EP2015/056824 WO2015150294A1 (en) 2014-03-31 2015-03-30 Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110640860.1A Division CN113521017A (zh) 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途

Publications (1)

Publication Number Publication Date
CN106572976A true CN106572976A (zh) 2017-04-19

Family

ID=50389975

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580017915.6A Pending CN106572976A (zh) 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途
CN202110640860.1A Pending CN113521017A (zh) 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110640860.1A Pending CN113521017A (zh) 2014-03-31 2015-03-30 包含生物蝶呤衍生物的固体药物组合物及此类组合物的用途

Country Status (28)

Country Link
US (6) US9895372B2 (cg-RX-API-DMAC7.html)
EP (2) EP2926805B1 (cg-RX-API-DMAC7.html)
JP (3) JP6552515B2 (cg-RX-API-DMAC7.html)
KR (1) KR102374500B1 (cg-RX-API-DMAC7.html)
CN (2) CN106572976A (cg-RX-API-DMAC7.html)
AU (2) AU2015239736B2 (cg-RX-API-DMAC7.html)
CA (1) CA2938267C (cg-RX-API-DMAC7.html)
CL (1) CL2016002463A1 (cg-RX-API-DMAC7.html)
CY (1) CY1117881T1 (cg-RX-API-DMAC7.html)
DK (1) DK2926805T3 (cg-RX-API-DMAC7.html)
ES (1) ES2586945T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20160802T1 (cg-RX-API-DMAC7.html)
HU (1) HUE030221T2 (cg-RX-API-DMAC7.html)
IL (1) IL248090B (cg-RX-API-DMAC7.html)
MX (1) MX377919B (cg-RX-API-DMAC7.html)
MY (1) MY180844A (cg-RX-API-DMAC7.html)
PE (1) PE20161253A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501519B1 (cg-RX-API-DMAC7.html)
PL (1) PL2926805T3 (cg-RX-API-DMAC7.html)
PT (1) PT2926805T (cg-RX-API-DMAC7.html)
RS (1) RS54973B1 (cg-RX-API-DMAC7.html)
RU (1) RU2694368C2 (cg-RX-API-DMAC7.html)
SA (1) SA516371933B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201606151SA (cg-RX-API-DMAC7.html)
SI (1) SI2926805T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600246B (cg-RX-API-DMAC7.html)
WO (1) WO2015150294A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605271B (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491635A (zh) * 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
CN114650825A (zh) * 2019-09-25 2022-06-21 Ptc医疗Mp公司 治疗高苯丙氨酸血症的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6382997B2 (ja) 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
PL2926805T3 (pl) 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji
JP2016168783A (ja) * 2015-03-13 2016-09-23 株式会社東芝 記録装置、記録方法、及び記録媒体
US12171766B2 (en) 2021-12-03 2024-12-24 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended Glasgow Outcome Scale of patients suffering from brain injury
JP6565103B2 (ja) * 2017-09-06 2019-08-28 株式会社昭和冷凍プラント 香気成分含有水溶液を含む液状製品の製造方法
WO2023099013A1 (en) 2021-12-03 2023-06-08 Verinos Operations Gmbh Methods of treating patients suffering from brain injury and methods of increasing the value of the extended glasgow outcome scale of patients suffering from brain injury
TW202406555A (zh) 2022-05-06 2024-02-16 德商ｖｅｒｉＮＯＳ運營有限公司 治療患有與增加的麩胺酸水平相關的疾病狀況或病症的患者的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
EP1757293A1 (en) * 2004-05-11 2007-02-28 Daiichi Asubio Pharma Co., Ltd. Bh4-responsive hyperphenylalaninemia remedies
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE201412T1 (de) 1997-10-06 2001-06-15 Ernst Werner Pteridinderivate als no synthase-hemmer
US6803046B2 (en) * 2002-08-16 2004-10-12 Bracco International B.V. Sincalide formulations
WO2005037286A1 (en) * 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
ES2755334T3 (es) * 2003-11-17 2020-04-22 Merck & Cie Proceso para la preparación de formas cristalinas B de clorhidrato de (6R)-L-eritro-tetrahidrobiopterina a partir de otras formas cristalinas
SE0401826D0 (sv) 2004-07-09 2004-07-09 Trimble Ab Method of preparing a winding for an n-phase motor
EP1669355A1 (en) * 2004-12-02 2006-06-14 Vasopharm Biotech GmbH Aminotetrahydropteridines and processes for manufacture thereof
EP2140731A2 (de) 2007-04-24 2010-01-06 Osram Gesellschaft mit Beschränkter Haftung Schaltungsanordnung zur zündung und zum betrieb einer entladungslampe
ES2736730T3 (es) 2008-08-12 2020-01-07 Orpha Swiss Gmbh Forma de administración farmacéutica que contiene tetrahidrobiopterina
WO2013033194A1 (en) * 2011-08-30 2013-03-07 Fresenius Kabi Usa, Llc Levothyroxine formulations
PL2926805T3 (pl) * 2014-03-31 2016-12-30 Stałe kompozycje farmaceutyczne zawierające pochodne biopteryny oraz zastosowania takich kompozycji

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922713A (en) * 1997-06-26 1999-07-13 Werner; Ernst Inhibition of nitric oxide synthase
EP1757293A1 (en) * 2004-05-11 2007-02-28 Daiichi Asubio Pharma Co., Ltd. Bh4-responsive hyperphenylalaninemia remedies
CN101132776A (zh) * 2004-11-17 2008-02-27 生物马林药物股份有限公司 稳定的四氢生物喋呤片剂制剂
CN101678025A (zh) * 2007-04-11 2010-03-24 生物马林药物股份有限公司 四氢生物蝶呤组合物及其测量方法
CN103458900A (zh) * 2011-03-01 2013-12-18 鲁必康研究私人有限公司 四氢生物蝶呤的稳定组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MICHAEL D. DAVIS等: "The auto-oxidation of tetrahydrobiopterin", 《EUR. J. BIOCHEM.》 *
NICOLE A. TERPOLILLI等: "The Novel Nitric Oxide Synthase Inhibitor 4-amino-tetrahydro-L-biopterine Prevents Brain Edema Formation and Intracranial Hypertension following Traumatic Brain Injury in Mice", 《JOURNAL OF NEUROTRAUMA》 *
吴梧桐: "《生物制药工艺学 3版》", 30 April 2013, 中国医药科技出版社 *
张连元 等: "《生理科学实验教程》", 31 January 2004, 人民军医出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111491635A (zh) * 2017-09-01 2020-08-04 显莎制药公司 包含墨蝶呤的药物组合物及其用途
CN114650825A (zh) * 2019-09-25 2022-06-21 Ptc医疗Mp公司 治疗高苯丙氨酸血症的方法

Also Published As

Publication number Publication date
PH12016501519A1 (en) 2017-02-06
BR112016020101A2 (cg-RX-API-DMAC7.html) 2017-07-15
CA2938267C (en) 2023-05-09
WO2015150294A1 (en) 2015-10-08
US9895372B2 (en) 2018-02-20
AU2015239736A1 (en) 2016-08-11
AU2020203880B2 (en) 2022-03-31
JP7178731B2 (ja) 2022-11-28
EP2926805B1 (en) 2016-05-18
SG11201606151SA (en) 2016-08-30
SA516371933B1 (ar) 2019-04-14
JP2021105062A (ja) 2021-07-26
RS54973B1 (sr) 2016-11-30
PL2926805T3 (pl) 2016-12-30
MX377919B (es) 2025-03-10
CN113521017A (zh) 2021-10-22
PE20161253A1 (es) 2016-11-13
US20220031703A9 (en) 2022-02-03
US12458644B2 (en) 2025-11-04
US10016431B2 (en) 2018-07-10
US20170112836A1 (en) 2017-04-27
CL2016002463A1 (es) 2017-01-27
RU2016141449A (ru) 2018-05-07
BR112016020101A8 (pt) 2021-06-29
HRP20160802T1 (hr) 2016-08-12
RU2016141449A3 (cg-RX-API-DMAC7.html) 2018-12-14
ZA201605271B (en) 2017-08-30
HUE030221T2 (en) 2017-04-28
US10493075B2 (en) 2019-12-03
AU2015239736B2 (en) 2020-03-26
US20200046710A1 (en) 2020-02-13
US20210137927A1 (en) 2021-05-13
AU2020203880A1 (en) 2020-07-02
ES2586945T3 (es) 2016-10-19
EP2926805A1 (en) 2015-10-07
JP2017509623A (ja) 2017-04-06
MX2016012784A (es) 2017-04-25
US20180289714A1 (en) 2018-10-11
CY1117881T1 (el) 2018-03-07
PH12016501519B1 (en) 2017-02-06
IL248090A0 (en) 2016-11-30
JP6879582B2 (ja) 2021-06-02
CA2938267A1 (en) 2015-10-08
KR102374500B1 (ko) 2022-03-15
JP2019194227A (ja) 2019-11-07
US20170296543A1 (en) 2017-10-19
DK2926805T3 (en) 2016-07-25
PT2926805T (pt) 2016-07-15
JP6552515B2 (ja) 2019-07-31
SI2926805T1 (sl) 2016-09-30
RU2694368C2 (ru) 2019-07-12
US10925877B2 (en) 2021-02-23
SMT201600246B (it) 2016-08-31
EP3125864A1 (en) 2017-02-08
IL248090B (en) 2019-10-31
HK1213195A1 (en) 2016-06-30
NZ722455A (en) 2022-03-25
KR20160138406A (ko) 2016-12-05
MY180844A (en) 2020-12-10
US20230355630A1 (en) 2023-11-09
US11717522B2 (en) 2023-08-08

Similar Documents

Publication Publication Date Title
JP7178731B2 (ja) ビオプテリン誘導体を含む固体薬学的組成物およびそのような組成物の使用
TWI686197B (zh) 包含生物蝶呤衍生物之固體醫藥組合物及該等組合物之用途
HK40056723A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1232799A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
HK1213195B (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
BR112016020101B1 (pt) Composição farmacêutica sólida, composição farmacêutica liofilizada, método para a preparação de uma composição farmacêutica liofilizada sólida, método para a preparação de uma solução injetável e uso da composição farmacêutica
NZ722455B2 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
EA030458B1 (ru) Лекарственная композиция цитопротекторного действия в виде водного раствора для внутривенного введения и способ ее получения
RU2466722C2 (ru) Противотуберкулезное средство

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1232799

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170419

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1232799

Country of ref document: HK